333 related articles for article (PubMed ID: 26255950)
21. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Charpentier G; Riveline JP; Dardari D; Varroud-Vial M
Drugs; 2006; 66(3):273-86. PubMed ID: 16526817
[TBL] [Abstract][Full Text] [Related]
22. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report.
Zheng MY; Yang JH; Shan CY; Zhou HT; Xu YG; Wang Y; Ren HZ; Chang BC; Chen LM
Cardiovasc Diabetol; 2013 May; 12():73. PubMed ID: 23642288
[TBL] [Abstract][Full Text] [Related]
23. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Dash RP; Babu RJ; Srinivas NR
Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
[TBL] [Abstract][Full Text] [Related]
24. An Updated Overview of Synthetic α-glucosidase Inhibitors: Chemistry and Bioactivities.
Cai YS; Xie HX; Zhang JH; Li Y; Zhang J; Wang KM; Jiang CS
Curr Top Med Chem; 2023; 23(26):2488-2526. PubMed ID: 37818579
[TBL] [Abstract][Full Text] [Related]
25. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
Toeller M
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
[TBL] [Abstract][Full Text] [Related]
26. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
27. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
28. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes.
Joshi SR; Ramachandran A; Chadha M; Chatterjee S; Rathod R; Kalra S
Expert Opin Pharmacother; 2014 Aug; 15(11):1611-20. PubMed ID: 24963542
[TBL] [Abstract][Full Text] [Related]
29. [Combination therapy with insulin and alpha-glucosidase inhibitor].
Watanabe K; Kawamori R
Nihon Rinsho; 2002 Sep; 60 Suppl 9():447-51. PubMed ID: 12387032
[No Abstract] [Full Text] [Related]
30. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.
Aoki K; Sato H; Terauchi Y
Endocr J; 2019 May; 66(5):395-401. PubMed ID: 31019154
[TBL] [Abstract][Full Text] [Related]
31. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Blicklé JF; Andres E; Brogard JM
Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Yamagishi S; Matsui T; Ueda S; Fukami K; Okuda S
Curr Drug Metab; 2009 Feb; 10(2):159-63. PubMed ID: 19275550
[TBL] [Abstract][Full Text] [Related]
33. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of black tea and its combination with acarbose on small intestinal α-glucosidase activity.
Satoh T; Igarashi M; Yamada S; Takahashi N; Watanabe K
J Ethnopharmacol; 2015 Feb; 161():147-55. PubMed ID: 25523370
[TBL] [Abstract][Full Text] [Related]
35. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes.
Breuer HW
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):421-40. PubMed ID: 14703948
[TBL] [Abstract][Full Text] [Related]
36. Newer insights into the drug delivery approaches of α-glucosidase inhibitors.
Kumar RV; Sinha VR
Expert Opin Drug Deliv; 2012 Apr; 9(4):403-16. PubMed ID: 22364261
[TBL] [Abstract][Full Text] [Related]
37. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
38. Acarbose: its role in the treatment of diabetes mellitus.
Campbell LK; White JR; Campbell RK
Ann Pharmacother; 1996 Nov; 30(11):1255-62. PubMed ID: 8913408
[TBL] [Abstract][Full Text] [Related]
39. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Hanefeld M; Schaper F
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
[TBL] [Abstract][Full Text] [Related]
40. Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update.
Usman B; Sharma N; Satija S; Mehta M; Vyas M; Khatik GL; Khurana N; Hansbro PM; Williams K; Dua K
Curr Pharm Des; 2019; 25(23):2510-2525. PubMed ID: 31333110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
